论文部分内容阅读
采用两种不同的免疫方案,分别取免疫的小鼠脾细胞进行融合,经筛选,分别得ALT-01,02,03和ALT-04,05,06,07,共7个不同的肺癌单克隆抗体。检测了它们与不同的体外培养的人肿瘤和正常的组织细胞系、人血细胞、人骨髓细胞、临床人肺癌组织标本、正常人的各组织器官的反应。ALT-01,04的选择性最好,与肺癌细胞有强阳性反应,而与人正常细胞、正常组织器官没有或仅与某些正常上皮细胞呈弱(±)反应。其中ALT-01与人肺癌组织及LTEP-78在无胸腺小鼠体内形成的肿瘤组织的反应均呈阴性;而ALT-04与30例临床标本中的25例呈阳性反应(83％),其中7例腺癌全部强阳性反应。核素~(125)I标记后的ALT-04在荷瘤小鼠体内浓集于癌灶部位,放射免疫定位获得清晰图像(r-成像)。
Using two different immunization protocols, the spleen cells of the immunized mice were fused and screened to obtain ALT-01, 02, 03 and ALT-04, 05, 06, 07, respectively, for a total of 7 different lung cancer monoclonals. antibody. They were tested for their response to various in vitro cultured human tumors and normal tissue cell lines, human blood cells, human bone marrow cells, clinical human lung cancer tissue samples, and normal tissues. ALT-01,04 has the best selectivity, strong positive reaction with lung cancer cells, and weak (±) response to human normal cells, normal tissue, or only some normal epithelial cells. The response of ALT-01 to human lung cancer tissues and LTEP-78 in the tumor tissue formed in athymic mice was negative; and ALT-04 was positive to 25 of the 30 clinical samples (83%). All 7 cases of adenocarcinoma were strongly positive. The radionuclide-immunolocalization of ALT-04-labeled ALT-04 in tumor-bearing mice concentrates at the site of tumor (r-imaging).